FOURLIGHT-1

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

May 17, 2024 → Oct 23, 2026

Cited window

May 17, 2024 → Oct 23, 2026

Retrieved

Oct 23, 2026

Title

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)

Registry

NCT06105632

Study IDs

C4391022 · 2023-506487-13-00 (CTIS (EU))

Sponsor

Pfizer

Design

Phase 2 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

333 actual

Start

2024-01-09 actual

Primary completion

2026-01-12 actual

Primary endpoint

Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, quoted posts and repeated announcement summaries cannot be counted as independent agreement.
• –Discussion that did not name the trial or familiar aliases, or used unusual spellings, may be absent. Some identified passages were not fully assessed for clinician views.
• –Clinical roles are not stated in the reviewed material for Atsushi Fushimi or Kristina Jankovic. Individual identities and HCP roles are not established for several accounts; their statements remain account-level commentary.
• –No full protocol or exact-trial results publication was available in the sources reviewed. Detailed methods, subgroup findings and comparative safety interpretations therefore cannot be independently assessed here.
• –No exact regulatory label for PF-07220060 was available in the reviewed material; this report does not establish an approved use.
• –Earlier posts reported 264 patients and later abstract-based summaries reported 263. The sources do not explain the difference.
• –Reports of 6.4% discontinuation and 4.0% treatment-related discontinuation should not be treated as interchangeable or as evidence of improvement over time.
• –Historical Phase 3 descriptions are preserved as contemporaneous descriptions, not evidence of Phase 3 efficacy or an explanation of the later Phase 2 designation.
• –Conditional PFS projections and indirect comparisons do not establish observed FOURLIGHT-1 medians or head-to-head rankings.
• –The ESMO 2026 sources include anticipatory posts and abstract-based commentary. They do not establish the presentation date or every post's timing relative to it, so the edition cannot be characterized as entirely preceding the presentation.

How reports are built and checked: Methods.

Last checked for new commentary Oct 23, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.